The largest population-based study to date supports the survival benefits of immunotherapy for people with metastatic non-small cell lung cancer
“Since the first immunotherapy drug to boost the body’s immune response against advanced lung cancer was introduced in the U.S. in 2015, survival rates of patients with the disease have improved significantly. That’s the conclusion of a recent real-world study published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.”
Clinical Lung Cancer Publishes Study: 93% of Oncologists Adjust Treatment Recommendations with OncoHost’s PROphetNSCLC™ Test
“BINYAMINA, Israel and CARY, N.C., July 29, 2024 /PRNewswire/ — OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced the publication of a study in Clinical Lung Cancer demonstrating the impact of its PROphetNSCLC™ test on first-line treatment decisions for metastatic non-small cell lung cancer (NSCLC) patients.”
Enhancing surgical precision in early-stage non-small cell lung cancer: A novel approach through temporary pulmonary vascular occlusion
“Conclusion: The technique, leveraging temporary pulmonary arteriovenous occlusion, offered a significant advancement in the surgical treatment of peripheral early-stage NSCLC. It reduced operation time and lowered overall surgical costs. This method represented a promising alternative to traditional surgical approaches.”
ODAC Votes to Require Trial Assessment of Neoadjuvant vs Adjuvant Benefits in Resectable NSCLC
“The FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted 11 to 0 that the regulatory body should require adequate within trial assessment of treatment phase contribution in new trial design proposals for perioperative regimens for resectable non–small cell lung cancer (NSCLC).”
Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance
“Not all MET exon 14 skipping (METex14) NSCLC patients benefited from MET inhibitors. We hypothesized an inter-tumoral heterogeneity in METex14 NSCLC. Investigations at genomic and transcriptomic level were conducted in METex14 NSCLC samples from stage I-III and recurrent/metastatic patients as discovery and validation cohort. Four molecular subtypes were discovered.”
23andMe, Advocacy Organizations Partner on Lung Cancer Genetics Study
“The study, according to a news release, is intended to increase understanding of the genetics of people with lung cancer in an effort to improve detection, risk reduction and care.”
Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment: Meeting Highlights
“The international meeting in Madrid of the newly formed Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE) was held in May 2024. This diverse forum included health-care professionals, public health leaders, industry representatives, and patient advocates from many nations to discuss the status and implementation challenges of low-dose computed tomography (CT) screening for lung cancer, including the opportunity to impact global health beyond reducing lung cancer mortality alone.”
State and Regional Trends in Incidence and Early Detection of Lung Cancer Among US Adults, 2010–2020
“Lung cancer is the leading cause of cancer death in both male and female adults in the US (1,2). Overall incidence rates of lung cancer continue to decline following historical declines in cigarette smoking, estimated to account for roughly 90% of lung cancer cases (3,4). However, disparities in incidence persist among certain racial and ethnic groups and between sexes.”
Examining Treatment Delay Trends in Patients With Lung Cancer
“An analysis published in the Journal of Clinical Oncology focusing on lung cancer patients in Missouri reveals a concerning increase in treatment initiation delays, exceeding national guidelines and calling for further investigation into potential causes.”
Video:
USC study explores at-home atezolizumab treatment for non-small cell lung cancer patients
“In a first-of-its-kind study, USC researchers are treating cancer patients in the comfort of their own home with a single shot therapy. Could this be the future of cancer care?”
